Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

abstract：:Recombinant human erythropoietin (rHuEpo) has been increasingly used in preterm infants in the last 3 to 4 years. Recent studies have indicated a reduction in blood transfusion requirements in infants receiving rHuEpo. No significant adverse effects have emerged, apart from iron deficiency (if iron supplementation is ...

journal_title：PharmacoEconomics

authors： Meyer MP

更新日期：1997-10-01 00:00:00

abstract：:There is a global perspective to the economic consequences of diabetes, which is illustrated in the many publications now being produced on this subject. Because of the higher prevalence of type II diabetes, its impact is greater than that of type I diabetes in both developed and developing countries (but particularly...

journal_title：PharmacoEconomics

authors： Williams R

更新日期：1995-01-01 00:00:00

abstract：BACKGROUND:The process of "mapping" is increasingly being used to predict health utilities, for application within health economic evaluations, using data on other indicators or measures of health. Guidance for the reporting of mapping studies is currently lacking. OBJECTIVE:The overall objective of this research was ...

journal_title：PharmacoEconomics

authors： Petrou S,Rivero-Arias O,Dakin H,Longworth L,Oppe M,Froud R,Gray A

更新日期：2015-10-01 00:00:00

abstract：:Hepatitis B virus (HBV) infection is an important public health problem all over the world. Vaccination is one way to prevent it, and several strategies can be used depending on endemicity, the main pattern of HBV transmission and the demographic structure of the population. In this study, an economic comparison of 3 ...

journal_title：PharmacoEconomics

authors： Antoñanzas F,Garuz R,Rovira J,Antón F,Trinxet C,Navas E,Salleras L

更新日期：1995-05-01 00:00:00

abstract：:Scientific reviewing methods were applied to economic studies of influenza vaccination, and an economic model of influenza vaccination was developed from these primary sources. Issues arising from the secondary literature review include the quality of evidence on the effectiveness of the vaccines, the absence of a tra...

journal_title：PharmacoEconomics

authors： Jefferson T,Demicheli V

更新日期：1996-01-01 00:00:00

abstract：OBJECTIVE:To estimate savings in the cost of caring for patients with Alzheimer's disease (AD) during 6 months, 1 year and 2 years of treatment with rivastigmine. An intermediate objective was to estimate the relationship between disease progression and institutionalisation. DESIGN AND SETTING:We assessed the relation...

journal_title：PharmacoEconomics

authors： Hauber AB,Gnanasakthy A,Snyder EH,Bala MV,Richter A,Mauskopf JA

更新日期：2000-04-01 00:00:00

abstract：BACKGROUND:Within the framework of economic evaluations, the transferability of utility scores between jurisdictions remains unclear. The EQ-5D is a generic instrument for measuring health-related quality of life in economic evaluations, which can be used for comparing utility scores across countries. At present, the E...

journal_title：PharmacoEconomics

authors： Knies S,Evers SM,Candel MJ,Severens JL,Ament AJ

更新日期：2009-01-01 00:00:00

abstract：INTRODUCTION AND OBJECTIVE:The National Cholesterol Education Program recommends regular physician follow-up and lipid testing to promote adherence with lipid-lowering medications. The objective of this study was to determine whether lipid tests and physician visits after treatment initiation are indeed associated with...

journal_title：PharmacoEconomics

authors： Benner JS,Tierce JC,Ballantyne CM,Prasad C,Bullano MF,Willey VJ,Erbey J,Sugano DS

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:A wide variety of oral antiplatelet trials have been carried out, and a large number of cost-effectiveness estimates based on them have been published. OBJECTIVE:To assess the cost effectiveness of oral antiplatelet treatments in the prevention of cardiovascular events. METHODS:A comprehensive literature s...

journal_title：PharmacoEconomics

authors： Heeg B,Damen J,Van Hout B

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Dengue disease poses a great economic burden in Malaysia. METHODS:This study evaluated the cost effectiveness and impact of dengue vaccination in Malaysia from both provider and societal perspectives using a dynamic transmission mathematical model. The model incorporated sensitivity analyses, Malaysia-speci...

journal_title：PharmacoEconomics

authors： Shafie AA,Yeo HY,Coudeville L,Steinberg L,Gill BS,Jahis R,Amar-Singh Hss

更新日期：2017-05-01 00:00:00

abstract：:The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of pazopanib hydrochloride (GlaxoSmithKline) to submit evidence of the clinical and cost effectiveness of the drug for the first-line treatment of advanced and/or metastatic renal cell carcinoma, as part of the Institute's single...

journal_title：PharmacoEconomics

authors： Kilonzo M,Hislop J,Elders A,Fraser C,Bissett D,McClinton S,Mowatt G,Vale L

更新日期：2013-01-01 00:00:00

abstract：:This study evaluated the cost utility of adding interferon-alpha 2b to conventional treatment in patients with multiple myeloma. It also provides a methodology for transforming complex quality-of-life profiles into a single index value on the conventional 0 to 1 quality-adjusted life-year scale (QALY). From 1990 to 19...

journal_title：PharmacoEconomics

authors： Nord E,Wisløff F,Hjorth M,Westin J

更新日期：1997-07-01 00:00:00

abstract：:In an attempt to obtain an appropriate estimate of the excess costs of production losses arising from morbidity in patients with diabetes, we compared the number of sick days and permanently disabled individuals in a diabetic population and the corresponding general population. These comparisons show that the rate of ...

journal_title：PharmacoEconomics

authors： Persson U

更新日期：1995-01-01 00:00:00

abstract：:This willingness-to-pay (WTP) analysis is the first study of its kind undertaken in Australia to support an application for listing of a new drug on the Australian national formulary. The technique offers the advantage of being able to summarise diverse outcomes of therapy in a single unit of measure. Willingness to p...

journal_title：PharmacoEconomics

authors： Davey P,Grainger D,MacMillan J,Rajan N,Aristides M,Dobson M

更新日期：1998-03-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Intensive insulin therapy improves glycosylated haemoglobin (Hb(A1C)) levels and delays the onset of long-term diabetes-related complications. Current treatment guidelines recommend maintaining a glycosylated haemoglobin (Hb(A1C)) of < or = 7% in patients with type 1 and 2 diabetes mellitus. Ho...

journal_title：PharmacoEconomics

authors： Grima DT,Thompson MF,Sauriol L

更新日期：2007-01-01 00:00:00

abstract：:This study examined the costs of treatment of, and quality of life in, patients with antineoplastic therapy-induced neutropenic fever who were treated with antibacterials, with or without granulocyte-macrophage colony-stimulating factor (GM-CSF). Patients with haematological malignancies (n = 47) or solid tumours (n =...

journal_title：PharmacoEconomics

authors： Uyl-de Groot CA,Vellenga E,de Vries EG,Löwenberg B,Stoter GJ,Rutten FF

更新日期：1997-09-01 00:00:00

abstract：AIM:To determine the economic impact (cost-benefit analysis) of childhood varicella vaccination, with the Oka/Merck varicella zoster virus vaccine live (Varivax) in Italy. METHODS:This analysis is based on an epidemiological model of varicella zoster virus (VZV) dynamics adapted to the Italian situation. Cost data (Eu...

journal_title：PharmacoEconomics

authors： Coudeville L,Brunot A,Giaquinto C,Lucioni C,Dervaux B

更新日期：2004-01-01 00:00:00

abstract：:Variable compliance with prescribed drug regimens is a leading source of variability in drug response. Specifics differ by drug and disease. The role of variable compliance was clearly defined in 2 trials of lipid-lowering agents, cholestyramine and gemfibrozil, in which exceptionally careful measurements of complianc...

journal_title：PharmacoEconomics

authors： Urquhart J

更新日期：1999-03-01 00:00:00

abstract：:Stroke remains the leading cause of neurological disability and the third leading cause of death worldwide, consuming a large share of total healthcare expenditures. In this review, we discuss the cost effectiveness of stroke prevention for various risk factor-modification programmes and pharmacological interventions ...

journal_title：PharmacoEconomics

authors： Alexandrov AV,Smurawska LT,Bartle W,Oh P

更新日期：1997-05-01 00:00:00

abstract：BACKGROUND:There is evidence that the earlier a patient reaches hospital and receives thrombolysis, the better the outcome. The GREAT (Grampian Region Early Anistreplase Trial) directly addressed the issue of early thrombolysis by evaluating, in a randomised controlled trial, the efficacy of thrombolysis in the communi...

journal_title：PharmacoEconomics

authors： Vale L,Steffens H,Donaldson C

更新日期：2004-01-01 00:00:00

abstract：:In a recent leading article in PharmacoEconomics, Nuijten described some methods for incorporating uncertainty into health economic models and for utilising the information on uncertainty regarding the cost effectiveness of a therapy in resource allocation decision-making. His proposals are found to suffer from seriou...

journal_title：PharmacoEconomics

authors： O'Hagan A,McCabe C,Akehurst R,Brennan A,Briggs A,Claxton K,Fenwick E,Fryback D,Sculpher M,Spiegelhalter D,Willan A

更新日期：2005-01-01 00:00:00

abstract：:Rheumatoid arthritis (RA) is a chronic, generally progressive autoimmune disease that causes functional disability, significant pain and joint destruction, and leads to premature mortality. It is estimated to affect between 0.5 and 1.0% of the adult population worldwide, increases in prevalence with age and affects mo...

journal_title：PharmacoEconomics

authors： Kvien TK

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:The ARTEMIS trial compared first-line antiretroviral therapy (ART) with lopinavir/ritonavir (LPV/r) to darunavir plus ritonavir (DRV + RTV) for HIV-1-infected subjects. In order to fully assess the implications of this study, economic modelling extrapolating over a longer term is required. OBJECTIVE:The aim...

journal_title：PharmacoEconomics

authors： Simpson KN,Pei PP,Möller J,Baran RW,Dietz B,Woodward W,Migliaccio-Walle K,Caro JJ

更新日期：2013-05-01 00:00:00

abstract：BACKGROUND:While drotrecogin alfa (activated) was shown to decrease absolute 28-day mortality by 6.1% in patients with severe sepsis in the Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study, no mortality benefit was observed in the subset of patients with only one organ system failure. C...

journal_title：PharmacoEconomics

authors： Betancourt M,McKinnon PS,Massanari RM,Kanji S,Bach D,Devlin JW

更新日期：2003-01-01 00:00:00

abstract：:Most countries have healthcare resource constraints and it is easy to identify new health technologies as an area in need of resource management, particularly given that new health technologies usually increase rather than save costs. Resource constraints are even more noticeable in Asia than in other regions, with a ...

journal_title：PharmacoEconomics

authors： Yang BM

更新日期：2009-01-01 00:00:00

abstract：:Our objective was to assess the quality of reporting of original economic research articles in PharmacoEconomics from inception to the end of 1995, in order to identify areas of strength and weakness, and analyse trends over time. Each regular issue of the journal was examined for original economic evaluations. Accept...

journal_title：PharmacoEconomics

authors： Iskedjian M,Trakas K,Bradley CA,Addis A,Lanctôt K,Kruk D,Ilersich AL,Einarson TR

更新日期：1997-12-01 00:00:00

abstract：:As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of vedolizumab (Takeda UK) to submit evidence of the clinical effectiveness and cost effectiveness of vedolizumab for the treatment of patients with moderate-to-severe active ...

journal_title：PharmacoEconomics

authors： Essat M,Tappenden P,Ren S,Bessey A,Archer R,Wong R,Lobo A,Hoque S

更新日期：2016-03-01 00:00:00

abstract：BACKGROUND:Pharmaceutical policy reform is currently one of the primary areas of health reform in China. The national pharmaceutical policy of China has multiple objectives: to develop the domestic pharmaceutical industry and encourage innovation, to control escalation of total pharmaceutical expenditures (TPE) which c...

journal_title：PharmacoEconomics

authors： Shi L,Yang HY,Cheng G,Meng Q

更新日期：2014-03-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to assess the cost effectiveness of using epoetin-alpha (erythropoietin) to augment preoperative autologous donation (PAD) of blood prior to elective cardiac surgery. DESIGN AND SETTING:We designed a decision-analytic model incorporating the risk of receiving allogeneic blood,...

journal_title：PharmacoEconomics

authors： Coyle D,Lee KM,Fergusson DA,Laupacis A

更新日期：2000-08-01 00:00:00

abstract：:This paper analyses the 32 technology appraisals completed by the National Institute for Clinical Excellence (NICE) in the UK from its establishment to the end of January 2002. It looks at why technologies have been rejected, what has happened to products reviewed at launch, evidence of rationing on cost-effectiveness...

journal_title：PharmacoEconomics

authors： Towse A,Pritchard C

更新日期：2002-01-01 00:00:00